Catalyst
Slingshot members are tracking this event:
Clovis (CLVS) Expects to Initiate Phase 2 STRAT-STAMPEDE Trial in 1H Evaluating Rucaparib in Prostate Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CLVS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 21, 2018
Occurred Source:
https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Preliminary-results-from-TRITON2-a-phase-2-study-of-rucaparib-in-patients-pts-with-metastatic-castration-resistant-prostate-cancer-mCRPC-associated-with-homologous-recombination-repair-HRR-gene-alterations
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rucaparib, Prostate Cancer, Phase 2, Strat-stampede
